Cargando…

Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy

BACKGROUND AND AIMS: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadokura, Makoto, Maekawa, Shinya, Sueki, Ryota, Miura, Mika, Komase, Kazuki, Shindo, Hiroko, Amemiya, Fumitake, Uetake, Tomoyoshi, Inoue, Taisuke, Sakamoto, Minoru, Nakagawa, Mina, Sakamoto, Naoya, Watanabe, Mamoru, Enomoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174186/
https://www.ncbi.nlm.nih.gov/pubmed/21935415
http://dx.doi.org/10.1371/journal.pone.0024514
_version_ 1782212043097505792
author Kadokura, Makoto
Maekawa, Shinya
Sueki, Ryota
Miura, Mika
Komase, Kazuki
Shindo, Hiroko
Amemiya, Fumitake
Uetake, Tomoyoshi
Inoue, Taisuke
Sakamoto, Minoru
Nakagawa, Mina
Sakamoto, Naoya
Watanabe, Mamoru
Enomoto, Nobuyuki
author_facet Kadokura, Makoto
Maekawa, Shinya
Sueki, Ryota
Miura, Mika
Komase, Kazuki
Shindo, Hiroko
Amemiya, Fumitake
Uetake, Tomoyoshi
Inoue, Taisuke
Sakamoto, Minoru
Nakagawa, Mina
Sakamoto, Naoya
Watanabe, Mamoru
Enomoto, Nobuyuki
author_sort Kadokura, Makoto
collection PubMed
description BACKGROUND AND AIMS: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and treatment outcome remains unclear. METHODS: The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct sequencing were investigated for correlation with the final outcome in a total of 60 patients. RESULTS: In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n = 16) were relapsers. Compared to sustained virological response (SVR) patients (n = 44), non-SVR patients were older and could not achieve prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted. Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid substitutions were associated with the final outcome in an incremental manner, depending upon the number of substitutions. CONCLUSIONS: Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of the ISDR, were extracted as having significant correlation with the final outcome.
format Online
Article
Text
id pubmed-3174186
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31741862011-09-20 Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy Kadokura, Makoto Maekawa, Shinya Sueki, Ryota Miura, Mika Komase, Kazuki Shindo, Hiroko Amemiya, Fumitake Uetake, Tomoyoshi Inoue, Taisuke Sakamoto, Minoru Nakagawa, Mina Sakamoto, Naoya Watanabe, Mamoru Enomoto, Nobuyuki PLoS One Research Article BACKGROUND AND AIMS: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and treatment outcome remains unclear. METHODS: The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct sequencing were investigated for correlation with the final outcome in a total of 60 patients. RESULTS: In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n = 16) were relapsers. Compared to sustained virological response (SVR) patients (n = 44), non-SVR patients were older and could not achieve prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted. Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid substitutions were associated with the final outcome in an incremental manner, depending upon the number of substitutions. CONCLUSIONS: Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of the ISDR, were extracted as having significant correlation with the final outcome. Public Library of Science 2011-09-15 /pmc/articles/PMC3174186/ /pubmed/21935415 http://dx.doi.org/10.1371/journal.pone.0024514 Text en Kadokura et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kadokura, Makoto
Maekawa, Shinya
Sueki, Ryota
Miura, Mika
Komase, Kazuki
Shindo, Hiroko
Amemiya, Fumitake
Uetake, Tomoyoshi
Inoue, Taisuke
Sakamoto, Minoru
Nakagawa, Mina
Sakamoto, Naoya
Watanabe, Mamoru
Enomoto, Nobuyuki
Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title_full Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title_fullStr Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title_full_unstemmed Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title_short Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy
title_sort analysis of the complete open reading frame of genotype 2b hepatitis c virus in association with the response to peginterferon and ribavirin therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174186/
https://www.ncbi.nlm.nih.gov/pubmed/21935415
http://dx.doi.org/10.1371/journal.pone.0024514
work_keys_str_mv AT kadokuramakoto analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT maekawashinya analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT suekiryota analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT miuramika analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT komasekazuki analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT shindohiroko analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT amemiyafumitake analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT uetaketomoyoshi analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT inouetaisuke analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT sakamotominoru analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT nakagawamina analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT sakamotonaoya analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT watanabemamoru analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy
AT enomotonobuyuki analysisofthecompleteopenreadingframeofgenotype2bhepatitiscvirusinassociationwiththeresponsetopeginterferonandribavirintherapy